Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Pradaxa (dabigatran etexilate) Patient Alert Card

Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.

Pradaxa (dabigatran etexilate) Prescriber guide for paediatric use for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age (paed. VTE)

This risk minimisation material provides recommendations for the use of Pradaxa for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age (paed. VTE) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa in the paediatric population and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

For Healthcare Professionals

Pradaxa (dabigatran etexilate) Prescriber Guide for stroke prevention in non-valvular atrial fibrillation (NVAF) and for the treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.